IgG4 Monoclonal Antibody
Oct 03, 2016
Taltz (Ixekizumab) in Treatment of Plaque psoriasis
Plaque psoriasis is a chronic autoimmune condition, with a buildup of dead cells as scales giving the affected area of skin a raised and red patchy look. About 2% of population in the US suffers from this disease. A new drug, Taltz (Ixekizumab), has been approved by FDA in March 2016 for its treatment. Taltz (ixekiz...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
